Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.52 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7354124 | 0.88 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4FPR2PROKR1 | |
| SCHEMBL10963570 | 0.83 | SLC6A3 (0.43) | SLC6A3SLC6A2SLC6A4FPR2PROKR1 | |
| SCHEMBL30945191 | 0.83 | SLC6A3 (0.43) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL8191324 | 0.83 | CHRNB4 (0.46) | SLC6A3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL21381761 | 0.82 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL2586181 | 0.81 | CHRNB4 (0.45) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL553892 | 0.77 | CHRM1 (0.40) | SLC6A3SLC6A2SLC6A4NOS3NOS1 | |
| SCHEMBL553891 | 0.77 | CHRM1 (0.40) | SLC6A3SLC6A2SLC6A4NOS3NOS1 | |
| SCHEMBL554969 | 0.77 | CHRM1 (0.40) | SLC6A3SLC6A2SLC6A4NOS3NOS1 | |
| SCHEMBL10460532 | 0.77 | SLC6A4 (0.55) | SLC6A3SLC6A2SLC6A4CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-18 | — | — | US | disclosed |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-21 | — | — | US | disclosed |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-01 | — | — | US | disclosed |
| EP-2855449-B1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-20160376256-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| US-9475795-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475795-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-23 | — | — | US | disclosed |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | SLC6A3 168/4885SLC6A2 460/4885SLC6A4 181/4885 |
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | SLC6A3 168/4885SLC6A2 460/4885SLC6A4 181/4885 |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | SLC6A3 168/4885SLC6A2 460/4885SLC6A4 181/4885 |
| US-20160376256-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | SLC6A3 168/4885SLC6A2 460/4885SLC6A4 181/4885 |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | SLC6A3 168/4885SLC6A2 460/4885SLC6A4 181/4885 |
| US-20150111922-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PGC | SLC6A3 396/4885SLC6A2 711/4885SLC6A4 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.